BOSTON (TheStreet) -- Investors got their first look at thousands of cancer drug research abstracts released Wednesday night by the American Society of Clinical Oncology (ASCO) in advance of its closely watched annual meeting.
Among the most significant cancer drug data unveiled for the first time Wednesday night came from phase III studies conducted by Aveo Pharmaceuticals (AVEO) and Exelixis (EXEL), and randomized phase II studies of drugs discovered by Array BioPharma (ARRY).
New disclosures of cancer drug data were also made available from Arqule (ARQL), Ariad Pharmaceuticals (ARIA), Pharmacyclics (PCYC), Onyx Pharmaceuticals (ONXX) and Seattle Genetics (SGEN), among many others.
The ASCO annual meeting runs June 1-5 and brings together cancer drug researchers from all over the world to discuss and present new clinical data aimed at treating -- and maybe one day curing -- cancer. Wednesday's release of research abstracts -- short, preliminary summaries of efficacy and safety data from cancer drug clinical trials -- serves as a warm-up for the big event next month.The ASCO abstract release is also a closely watched event for Wall Street because the revelation of new cancer drug data often has a significant effect on biotech and drug stocks. Trading volatility can ramp up significantly for many of the so-called "ASCO stocks" -- particularly small-cap biotech stocks -- in the weeks before the ASCO confab gets started. While investors were flooded with new cancer drug data Wednesday, ASCO did hold back some of the some important and potentially stock-moving research for a more high-profile release at the meeting itself. Key cancer drug data that remains under wrap include results from a phase III study of Johnson & Johnson's (JNJ) Zytiga in "pre-chemo" prostate cancer patients; a phase III study of Bayer and Onyx's regorafenib in advanced gastrointestinal stromal tumors; several Roche/Genentech (RHHBY) studies, including Avastin in ovarian cancer and TDM-1 in breast cancer (partnered with Immunogen (IMGN)); melanoma data from GlaxoSmithKline's (GSK) targeted drug dabrefenib; and a new targeted PD-1 immunotherapy from Bristol-Myers Squibb (BMY). The following pages summarize new and important cancer drug data released tonight by ASCO from research abstracts for its upcoming annual meeting. Array BioPharma What we already know: Last September, Array partner AstraZeneca (AZN) announced top-line results from a phase II non-small cell lung cancer study of selumetinib, in which the combination of selumetinib plus docetaxel demonstrated a "numerically greater increase" in survival compared to docetaxel alone. Patients in the study had non-small cell lung cancer with a mutation in the KRAS gene, which makes the tumors harder to treat. What's new in the ASCO abstracts: Median overall survival in the selumetinib/docetaxel arm was 9.4 months compared to 5.2 months for docetaxel alone -- a difference of 4.2 months but not statistically significant. Response rate (37% vs. 0%) and progression-free survival (5.3 months vs. 2.1 months) both favored selumetinib/docetaxel over docetaxel alone with statistical significance. (Abstract No. 7503) Additional ASCO abstracts of note: Take a look at Abstract No. 8511, which reports on early results of a phase II study investigating MEK162 in patients with cutaneous melanoma harboring one of two genetic mutations: BRAFV600 or NRAS. MEK162 is a drug developed by Array and licensed to Novartis (NVS). Among 29 BRAF-mutant melanoma patients treated with MEK162, there were 1 confirmed and 6 unconfirmed partial responses and 9 patients with stable disease. Among 13 NRAS mutant patients, there were 2 confirmed and 1 unconfirmed partial responses and 4 patients with stable disease.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV